tirzepatide – Page 2

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

By MedXY 08/30/2025

Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy

By MedXY 07/29/2025

A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.